Literature DB >> 6168653

Detection of a new heparin-dependent inhibitor of thrombin in human plasma.

D M Tollefsen, M K Blank.   

Abstract

We have demonstrated that human plasma contains a heparin-dependent inhibitor of thrombin that is distinguishable from antithrombin III (AT III). When a 1:50 dilution of plasma was incubated with greater than or equal to 0.01 U/ml heparin and 1 U/ml 125I-thrombin, the labeled thrombin B-chains became incorporated into two complexes of Mr-96,000 and Mr-85,000 that were separated by polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate and beta-mercaptoethanol. Neither complex was detectable at heparin concentrations less than 0.01 U/ml. When a limiting amount of 125I-thrombin was present, the proportion of radioactivity incorporated into each of the two complexes varied with the heparin concentration. Thus, the Mr-85,000 complex predominated at 0.01-5 U/ml heparin, whereas the Mr-96,000 complex predominated at 5-100 U/ml heparin. The Mr-85,000 complex reacted with antibodies to human AT III and comigrated with the purified thrombin-AT III complex. The Mr-96,000 complex did not react with antibodies to AT III or to alpha 1-antitrypsin, and it was detected in normal quantities after incubating 125I-thrombin with plasma immunodepleted of AT III, alpha 2-antiplasmin, alpha 2-macroglobulin, C1 inactivator, alpha 1-antichymotrypsin, or inter-alpha-trypsin inhibitor. The protein that combines with thrombin to form the Mr-96,000 complex was estimated to be present at a minimum concentration of 90 +/- 26 micrograms/ml (mean +/- SD) in identical to any of the known plasma protease inhibitors and that at relatively high heparin concentrations in vitro it reacts with thrombin more rapidly than does AT III.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6168653      PMCID: PMC370838          DOI: 10.1172/jci110292

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  28 in total

Review 1.  Biologic actions of heparin.

Authors:  R D Rosenberg
Journal:  Semin Hematol       Date:  1977-10       Impact factor: 3.851

2.  Hirudin.

Authors:  D Bagdy; E Barabas; L Gráf; T E Petersen; S Magnusson
Journal:  Methods Enzymol       Date:  1976       Impact factor: 1.600

3.  Routes of thrombin action in the production of proteolytically modified, secondary forms of antithrombin-thrombin complex.

Authors:  W W Fish; K Orre; I Björk
Journal:  Eur J Biochem       Date:  1979-11-01

4.  Properties of antithrombin III depleted plasma. I. Effect of heparin.

Authors:  E Holmer; G Söderström; L O Andersson
Journal:  Thromb Res       Date:  1980 Jan 1-15       Impact factor: 3.944

5.  The isolation and characterization of a specific antibody population directed against the thrombin antithrombin complex.

Authors:  H K Lau; R D Rosenberg
Journal:  J Biol Chem       Date:  1980-06-25       Impact factor: 5.157

6.  X-ray intensifying screens greatly enhance the detection by autoradiography of the radioactive isotopes 32P and 125I.

Authors:  R Swanstrom; P R Shank
Journal:  Anal Biochem       Date:  1978-05       Impact factor: 3.365

7.  Human thrombins. Production, evaluation, and properties of alpha-thrombin.

Authors:  J W Fenton; M J Fasco; A B Stackrow
Journal:  J Biol Chem       Date:  1977-06-10       Impact factor: 5.157

8.  Dissociation of complexes and their derivatives formed during inhibition of bovine thrombin and activated factor X by antithrombin III.

Authors:  J Jesty
Journal:  J Biol Chem       Date:  1979-02-25       Impact factor: 5.157

9.  Fractionation of low molecular weight heparin species and their interaction with antithrombin.

Authors:  D Beeler; R Rosenberg; R Jordan
Journal:  J Biol Chem       Date:  1979-04-25       Impact factor: 5.157

10.  Cell membrane antigen isolation with the staphylococcal protein A-antibody adsorbent.

Authors:  S W Kessler
Journal:  J Immunol       Date:  1976-11       Impact factor: 5.422

View more
  18 in total

Review 1.  The hemostatic defect of cardiopulmonary bypass.

Authors:  Matthew Dean Linden
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

2.  Anti-thrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin.

Authors:  B Bray; D A Lane; J M Freyssinet; G Pejler; U Lindahl
Journal:  Biochem J       Date:  1989-08-15       Impact factor: 3.857

3.  A simple two-step purification of protease nexin.

Authors:  D H Farrell; W E Van Nostrand; D D Cunningham
Journal:  Biochem J       Date:  1986-08-01       Impact factor: 3.857

4.  Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate.

Authors:  F A Ofosu; G J Modi; M A Blajchman; M R Buchanan; E A Johnson
Journal:  Biochem J       Date:  1987-12-15       Impact factor: 3.857

5.  Inhibition of chymotrypsin by heparin cofactor II.

Authors:  F C Church; C M Noyes; M J Griffith
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

Review 6.  Mechanism of the anticoagulant action of heparin.

Authors:  I Björk; U Lindahl
Journal:  Mol Cell Biochem       Date:  1982-10-29       Impact factor: 3.396

7.  Modulation of heparin cofactor II activity by histidine-rich glycoprotein and platelet factor 4.

Authors:  D M Tollefsen; C A Pestka
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

8.  Heparin-catalyzed inhibitor/protease reactions: kinetic evidence for a common mechanism of action of heparin.

Authors:  M J Griffith
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

9.  Non-enzymatic glycation reduces heparin cofactor II anti-thrombin activity.

Authors:  A Ceriello; E Marchi; M Barbanti; M R Milani; D Giugliano; A Quatraro; P Lefebvre
Journal:  Diabetologia       Date:  1990-04       Impact factor: 10.122

10.  Evidence of normal functional levels of activated protein C inhibitor in combined Factor V/VIII deficiency disease.

Authors:  W M Canfield; W Kisiel
Journal:  J Clin Invest       Date:  1982-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.